The Effect of Age on Response to Therapy With Peginterferon α Plus Ribavirin in a Cohort of Patients With Chronic HCV Hepatitis Including Subjects Older Than 65 Yr

@article{Antonucci2007TheEO,
  title={The Effect of Age on Response to Therapy With Peginterferon α Plus Ribavirin in a Cohort of Patients With Chronic HCV Hepatitis Including Subjects Older Than 65 Yr},
  author={Giorgio Antonucci and Maria Antonella Longo and Claudio Angeletti and Francesco Vairo and Alessandra Oliva and Ubaldo Visco Comandini and Guido Tocci and Evangelo Boumis and Pasquale Noto and Maria Carmela Solmone and Maria Rosaria Capobianchi and Enrico Girardi},
  journal={The American Journal of Gastroenterology},
  year={2007},
  volume={102},
  pages={1383-1391}
}
OBJECTIVES:In many industrialized countries HCV infection is characterized by an increasing prevalence during ageing; however, data on the efficacy of treatment among older patients are scarce. This study was set up to evaluate the effect of age on the treatment of chronic HCV hepatitis with peginterferon α plus ribavirin.METHODS:We retrospectively reviewed medical records of 153 adult patients with chronic HCV hepatitis treated with combination therapy; 30 of them (19.6%) were 65 years of age… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 35 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 38 references

Peginterferon-alpha2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis

  • M von Wagner, M Huber, T Berg
  • C. Gastroenterology
  • 2005
1 Excerpt

Similar Papers

Loading similar papers…